3-AMINO 3H-ISOBENZOFURANONE

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 3-AMINO 3H-ISOBENZOFURANONE
• 英文别名: 3-aminophthalide；aminophthalide；3-amino-3H-2-benzofuran-1-one
• 化学式: C₈H₇NO₂
• 分子量: 149.149
• InChiKey: OEIOKPQWHXSUCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-AMINO 3H-ISOBENZOFURANONE 、 阿司匹林 以 环己烷 、 异丙醇 为溶剂， 反应 6.0h， 以89%的产率得到
  参考文献：
  名称：

  一种他洛柳酯药物中间体2-乙酰氧基苯甲酸-3-羟基苯酞酯的合成方法

  摘要：

  一种他洛柳酯药物中间体2-乙酰氧基苯甲酸-3-羟基苯酞酯的合成方法，包括如下步骤：在安装有搅拌器、回流冷凝器的反应容器中，加入乙酰水杨酸(2)0.24mol,3-胺苯酞(3)0.24—0.27mol,异丙醇30—40ml,环己烷230—260ml,控制搅拌速度130—160rpm,回流4—6h,常压蒸出环己烷，再减压蒸馏蒸出固体，用盐溶液洗涤固体，抽滤，用乙酸乙酯重结晶，得白色固体2-乙酰氧基苯甲酸-3-羟基苯酞酯(1)；其中，步骤所述的异丙醇的质量分数为65—70％，步骤所述的环己烷的质量分数为45—50％。

  公开号：

  CN105503799A

文献信息

• A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG
  申请人：Shionogi & Co., Ltd.

  公开号：US20200261481A1

  公开（公告）日：2020-08-20

  A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A 1 is CR 1A R 1B , S or O; A 2 is CR 2A R 2B , S or O; A 3 is CR 3A R 3B , S or O; A 4 is each independently CR 4A R 4B , S or O; the number of hetero atoms among atoms constituting the ring which consists of A 1 , A 2 , A 3 , A 4 , nitrogen atom adjacent to A 1 and carbon atom adjacent to A 4 is 1 or 2; R 1A and R 1B are each independently hydrogen, halogen, alkyl or the like; R 2A and R 2B are each independently hydrogen, halogen, alkyl, or the like; R 3A and R 3B are each independently hydrogen, halogen, alkyl, or the like; R 4A are each independently hydrogen, halogen, alkyl, or the like; R 4B are each independently hydrogen, halogen, alkyl, or the like; R 3A and R 3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R 1 is or the like, is combined with (B) compound(s) having an anti-influenza activity, its pharmaceutically acceptable salt or a solvate thereof and/or an antibody having anti-influenza activity, is useful for treating or preventing influenza.

  一种药物，其特征在于（A）由以下式（I）表示的化合物： 其药学上可接受的盐，或其溶剂合物， 其中 P为氢或形成前药的基团; A 1 为CR 1A R 1B 、S或O; A 2 为CR 2A R 2B 、S或O; A 3 为CR 3A R 3B 、S或O; A 4 分别为独立的CR 4A R 4B 、S或O; 构成由A 1 、A 2 、A 3 、A 4 、邻接到A 1 的氮原子和邻接到A 4 的碳原子的环的原子中的杂原子数为1或2; R 1A 和R 1B 分别为独立的氢、卤素、烷基或类似物; R 2A 和R 2B 分别为独立的氢、卤素、烷基或类似物; R 3A 和R 3B 分别为独立的氢、卤素、烷基或类似物; R 4A 分别为独立的氢、卤素、烷基或类似物; R 4B 分别为独立的氢、卤素、烷基或类似物; R 3A 和R 3B 可以与相邻的碳原子结合形成非芳香碳环或非芳香杂环; n为1到2的任意整数; 和 R 1 为 或类似物， 与具有抗流感活性的（B）化合物，其药学上可接受的盐或其溶剂合物和/或具有抗流感活性的抗体结合，用于治疗或预防流感。
• LIGHT-DRIVEN ROTARY MOLECULAR MOTORS
  申请人：Bell Thomas W.

  公开号：US20110077394A1

  公开（公告）日：2011-03-31

  Compounds of Formula (1) are disclosed. C b is a carbocyclic or heterocyclic group having an atom within the cyclic structure selected from C, N, Si, and C r and singly bound to A. A is CR, COR, CSR, CNR 2 , CCN, CCONR 2 , CNO 2 , CNNAr, CX′, or N. C r is a chromophore having a substantially planar cyclic structure. The compounds function as nanometer-scale rotary molecular motors powered and controlled by light energy. The design of the molecular motor devices is flexible so that the rotary direction, drive light wavelength, and other physical characteristics can be varied. The compounds can be chemically functionalized to allow it to be integrated into or attached to a variety of structures. The device can be used in applications where mechanical power, positional control, and information encoding are to be generated at the size scale of individual molecules.

  式（1）的化合物已被披露。 C b 是一个具有环结构内选自C、N、Si和C r 的原子的碳环或杂环基团，并与A单键相连。A是CR、COR、CSR、CNR 2 、CCN、CCONR 2 、CNO 2 、CNNAr、CX′或N。C r 是具有基本平面环结构的色团。这些化合物作为受光能驱动和控制的纳米尺度旋转分子马达。分子马达装置的设计灵活，使得旋转方向、驱动光波长和其他物理特性可以变化。这些化合物可以在化学上官能化，以使其能够集成到或附着到各种结构中。该装置可用于需要在单个分子尺度上产生机械动力、位置控制和信息编码的应用中。
• Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20030232823A1

  公开（公告）日：2003-12-18

  A compound of Formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  一种化合物，其化学式为（I）1，其中R1、R2、R3、R4、R5和R6如本文所定义，或其互变异构体、前药、溶剂化合物或盐，包含这种化合物的药物组合物，以及使用这些化合物调节糖皮质激素受体功能的方法，以及使用这些化合物治疗由糖皮质激素受体功能介导的疾病状态或条件，或由炎症、过敏或增生过程特征的患者的方法。
• Urea thiadiazole inhibitors of plasminogen activator inhibior-1
  申请人：Sartori Eric

  公开号：US20050124664A1

  公开（公告）日：2005-06-09

  Methods of treating disorders associated with elevated levels of PAI-1 are disclosed comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula (I), or a pharmaceutically-acceptable salt, prodrug, stereoisomer or solvate thereof, wherein: A is aryl o heteroaryl, and R 1 -R 12 , are defined herein. The invention also pertains to pharmaceutical compositions and compounds within the scope of formula (I) as well as medicaments and articles of manufacture comprising compounds of formula (I).

  揭示了治疗与PAI-1水平升高相关的疾病的方法，包括向需要治疗的患者施用至少一种式(I)的化合物的治疗有效量，或者其药用盐、前药、立体异构体或溶剂化合物，其中：A是芳基或杂芳基，R1-R12在此处定义。该发明还涉及范围在式(I)内的药物组合物和化合物，以及包含式(I)化合物的药物和制造物。
• Nonsteroidal anti-inflammatory agents
  申请人：Schering Aktiengesellschaft

  公开号：US06323199B1

  公开（公告）日：2001-11-27

  This invention describes the use of the compounds of general formula I in which A, B, A, Ar, R1, R2 and R3 have the meaning that is indicated in more detail in the description, for the production of pharmaceutical agents with anti-inflammatory action. The compounds of general formula I show a clear dissociation between anti-inflammatory and metabolic action.

  这项发明描述了一般式I中化合物的使用，其中A、B、A、Ar、R1、R2和R3的含义在描述中有更详细的说明，用于生产具有抗炎作用的药物。一般式I中的化合物显示出抗炎和代谢作用之间的明显分离。